Patient Characteristics
| Patient No. . | FAB Type . | Sex/Age (yr) . | PB/BM . | % of Blasts* . | Response to Therapy . | HB-EGF mRNA† . | DT Sensitivity‡ . | CD91-153 . | HER-11-153 . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | M0 | M/61 | PB | 95 | No | + | + | − | − |
| 2 | M0 | F/56 | PB | 90 | CR | + | + | nd | − |
| 3 | M1 | F/67 | PB | 95 | CR | + | + | − | − |
| 4 | M1 | M/27 | PB | 100 | CR | − | − | − | nd |
| 5 | M1 | M/24 | PB | 93 | No | + | + | − | − |
| 6 | M2 | F/69 | PB | 100 | CR | − | − | nd | nd |
| 7 | M2 | F/62 | PB | 90 | CR | + | − | − | nd |
| 8 | M3 | F/43 | BM | 95 | CR | + | + | nd | − |
| 9 | M4 | M/70 | PB | 95 | No | + | + | − | nd |
| 10 | M4 | M/66 | PB | 95 | CR | − | − | + | nd |
| 11 | M5 | M/75 | PB | 90 | No | + | + | + | − |
| 12 | M5 | M/43 | PB | 99 | CR | − | − | nd | − |
| Patient No. . | FAB Type . | Sex/Age (yr) . | PB/BM . | % of Blasts* . | Response to Therapy . | HB-EGF mRNA† . | DT Sensitivity‡ . | CD91-153 . | HER-11-153 . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | M0 | M/61 | PB | 95 | No | + | + | − | − |
| 2 | M0 | F/56 | PB | 90 | CR | + | + | nd | − |
| 3 | M1 | F/67 | PB | 95 | CR | + | + | − | − |
| 4 | M1 | M/27 | PB | 100 | CR | − | − | − | nd |
| 5 | M1 | M/24 | PB | 93 | No | + | + | − | − |
| 6 | M2 | F/69 | PB | 100 | CR | − | − | nd | nd |
| 7 | M2 | F/62 | PB | 90 | CR | + | − | − | nd |
| 8 | M3 | F/43 | BM | 95 | CR | + | + | nd | − |
| 9 | M4 | M/70 | PB | 95 | No | + | + | − | nd |
| 10 | M4 | M/66 | PB | 95 | CR | − | − | + | nd |
| 11 | M5 | M/75 | PB | 90 | No | + | + | + | − |
| 12 | M5 | M/43 | PB | 99 | CR | − | − | nd | − |
Abbreviations: M, male; F, female; PB, peripheral blood; BM, bone marrow; CR, complete remission; nd, not done.
In vivo.
By Northern blot.
Blasts were considered to be sensitive (+) to DT when more than 50% of them were killed with a typical dose-response curve in the 10−11 to 10−8 mol/L DT concentration range during a 48-hour period, as evaluated by the MTT assay.
By flow cytometry.